Show simple item record

dc.contributor.authorZucca, E
dc.contributor.authorConconi, A
dc.contributor.authorMughal, Tariq I
dc.contributor.authorSarris, A H
dc.contributor.authorSeymour, J F
dc.contributor.authorVitolo, U
dc.contributor.authorKlasa, R
dc.contributor.authorOzsahin, M
dc.contributor.authorMead, Graham M
dc.contributor.authorGianni, M A
dc.contributor.authorCortelazzo, S
dc.contributor.authorFerreri, A J M
dc.contributor.authorAmbrosetti, A
dc.contributor.authorMartelli, M
dc.contributor.authorThiéblemont, C
dc.contributor.authorMoreno, H Gomez
dc.contributor.authorPinotti, G
dc.contributor.authorMartinelli, Giovanni
dc.contributor.authorMozzana, R
dc.contributor.authorGrisanti, S
dc.contributor.authorProvencio, M
dc.contributor.authorBalzarotti, M
dc.contributor.authorLaveder, F
dc.contributor.authorOltean, G
dc.contributor.authorCallea, V
dc.contributor.authorRoy, P
dc.contributor.authorCavalli, Franco
dc.contributor.authorGospodarowicz, M
dc.date.accessioned2009-08-26T15:06:58Z
dc.date.available2009-08-26T15:06:58Z
dc.date.issued2003-01-01
dc.identifier.citationPatterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. 2003, 21 (1):20-7 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid12506165
dc.identifier.doi10.1200/JCO.2003.11.141
dc.identifier.urihttp://hdl.handle.net/10541/78753
dc.description.abstractPURPOSE: To determine clinical features and patterns of outcome of primary testicular diffuse large B-cell lymphomas (DLCL). PATIENTS AND METHODS: A retrospective international survey of 373 patients with primary testicular DLCL. RESULTS: Most patients presented with localized disease (stage I to II), and the median age at diagnosis was 66 years (range, 19 to 91 years). Anthracycline-based chemotherapy was administered to 255 patients (68%), and prophylactic intrathecal chemotherapy was given to 68 patients (18%); 133 patients (36%) received prophylactic scrotal radiotherapy. Median overall survival was 4.8 years, and median progression-free survival was 4 years. The survival curves showed no clear evidence of a substantial proportion of cured patients. A favorable international prognostic index score (IPI), no B-symptoms, the use of anthracyclines, and prophylactic scrotal radiotherapy were significantly associated with longer survival at multivariate analysis. However, even for patients with stage I disease and good-risk IPI, the outcome seems worse than what was reported for DLCL at other sites. At a median follow-up of 7.6 years, 195 patients (52%) had relapsed. Extranodal recurrence was reported in 140 cases. Relapses in CNS were detected in 56 patients (15%) up to 10 years after presentation. A continuous risk of recurrence in the contralateral testis was seen in patients not receiving scrotal radiotherapy. CONCLUSION: Testicular DLCL is characterized by a particularly high risk of extranodal relapse even in cases with localized disease at diagnosis. Anthracycline-based chemotherapy, CNS prophylaxis, and contralateral testicular irradiation seem to improve the outcome. Their efficacy is under evaluation in a prospective clinical trial.
dc.language.isoenen
dc.subjectTesticular Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnalysis of Variance
dc.subject.meshDisease-Free Survival
dc.subject.meshHumans
dc.subject.meshLymphoma, Large B-Cell, Diffuse
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshRecurrence
dc.subject.meshRetrospective Studies
dc.subject.meshSurvival Rate
dc.subject.meshTesticular Neoplasms
dc.subject.meshTreatment Outcome
dc.titlePatterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.en
dc.typeArticleen
dc.contributor.departmentDivision of Haematology/Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Australia. ielsg@ticino.comen
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPURPOSE: To determine clinical features and patterns of outcome of primary testicular diffuse large B-cell lymphomas (DLCL). PATIENTS AND METHODS: A retrospective international survey of 373 patients with primary testicular DLCL. RESULTS: Most patients presented with localized disease (stage I to II), and the median age at diagnosis was 66 years (range, 19 to 91 years). Anthracycline-based chemotherapy was administered to 255 patients (68%), and prophylactic intrathecal chemotherapy was given to 68 patients (18%); 133 patients (36%) received prophylactic scrotal radiotherapy. Median overall survival was 4.8 years, and median progression-free survival was 4 years. The survival curves showed no clear evidence of a substantial proportion of cured patients. A favorable international prognostic index score (IPI), no B-symptoms, the use of anthracyclines, and prophylactic scrotal radiotherapy were significantly associated with longer survival at multivariate analysis. However, even for patients with stage I disease and good-risk IPI, the outcome seems worse than what was reported for DLCL at other sites. At a median follow-up of 7.6 years, 195 patients (52%) had relapsed. Extranodal recurrence was reported in 140 cases. Relapses in CNS were detected in 56 patients (15%) up to 10 years after presentation. A continuous risk of recurrence in the contralateral testis was seen in patients not receiving scrotal radiotherapy. CONCLUSION: Testicular DLCL is characterized by a particularly high risk of extranodal relapse even in cases with localized disease at diagnosis. Anthracycline-based chemotherapy, CNS prophylaxis, and contralateral testicular irradiation seem to improve the outcome. Their efficacy is under evaluation in a prospective clinical trial.


This item appears in the following Collection(s)

Show simple item record